Alexion Announces Appointment of Tanisha Carino, Ph.D., as Chief Corporate Affairs Officer
October 10 2019 - 4:01PM
Business Wire
- Dr. Carino to head up newly integrated
Corporate Affairs function including global government affairs,
public policy and communications -
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the
appointment of Tanisha Carino, Ph.D., as Executive Vice President
and the company’s first Chief Corporate Affairs Officer. Dr. Carino
will join Alexion on November 4, 2019 and will serve on the
company’s Executive Committee. In her role, Dr. Carino will oversee
the creation of a newly integrated Corporate Affairs function that
encompasses Alexion’s corporate affairs activities, including
high-level relations with domestic and international governments
and global communications.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20191010005839/en/
(Photo: Business Wire)
“I am delighted that Tanisha will be joining Alexion and our
Executive Committee. Her extensive experience advocating for the
development of medicines for rare diseases and the rare disease
community will be instrumental as Alexion enters our next chapter,
with our significantly expanded and diversified pipeline that
provides the opportunity to serve more patients than ever before,”
said Ludwig Hantson, Ph.D., Chief Executive Officer at Alexion.
“The creation of this new role represents our continued commitment
to elevating our leadership in rare disease and our desire for
enhanced engagement with governments and other stakeholders to
support the role transformative science brings to people affected
by rare diseases.”
“For nearly 30 years, Alexion has been at the forefront of
developing medicines for rare diseases,” said Dr. Carino. “I am
excited to join a company with such an unwavering focus on patients
and look forward to helping advance the company’s mission of
transforming the lives of people with rare diseases.”
Throughout her distinguished career, Dr. Carino has been at the
forefront of collaborative efforts to promote policies, research,
and business practices supporting the fight against disease and
improving the lives of patients. Prior to joining Alexion, Dr.
Carino served as the Executive Director of FasterCures, a Center of
the Milken Institute, whose mission is to put patients in the
center of the healthcare system, break down unnecessary barriers to
innovation, and accelerate biomedical research. Prior to leading
FasterCures, Dr. Carino was an executive at GlaxoSmithKline where
she led the United States policy function and prior to that, spent
over a decade with Avalere Health, a strategic advisory services
organization, where she worked with senior leaders of life sciences
companies to maximize opportunities and mitigate challenges related
to biomedical research and patient access. Dr. Carino is a
Fulbright Fellow, earned her Ph.D. in health policy from Johns
Hopkins University, and is associate faculty at the Johns Hopkins
Bloomberg School of Public Health.
About Alexion Alexion is a global biopharmaceutical
company focused on serving patients and families affected by rare
diseases through the discovery, development and commercialization
of life-changing therapies. As the global leader in complement
biology and inhibition for more than 20 years, Alexion has
developed and commercializes two approved complement inhibitors to
treat patients with paroxysmal nocturnal hemoglobinuria (PNH) as
well as the first and only approved complement inhibitor to treat
atypical hemolytic uremic syndrome (aHUS), anti-acetylcholine
receptor (AchR) antibody-positive generalized myasthenia gravis
(gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion
also has two highly innovative enzyme replacement therapies for
patients with life-threatening and ultra-rare metabolic disorders,
hypophosphatasia (HPP) and lysosomal acid lipase deficiency
(LAL-D). In addition, the company is developing several
mid-to-late-stage therapies, including a second complement
inhibitor, a copper-binding agent for Wilson disease and an
anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G
(IgG)-mediated diseases as well as several early-stage therapies,
including one for light chain (AL) amyloidosis and a second
anti-FcRn therapy. Alexion focuses its research efforts on novel
molecules and targets in the complement cascade and its development
efforts on the core therapeutic areas of hematology, nephrology,
neurology, and metabolic disorders. Alexion has been named to the
Forbes’ list of the World’s Most Innovative Companies seven years
in a row and is headquartered in Boston, Massachusetts’ Innovation
District. The company also has offices around the globe and serves
patients in more than 50 countries. This press release and further
information about Alexion can be found at: www.alexion.com.
[ALXN-G]
Forward-Looking Statement This press release contains
forward-looking statements that involve risks and uncertainties
relating to future events and the future performance of Alexion,
including statements related to: Alexion’s commitment to elevating
its leadership in rare disease and its desire for enhanced
partnership with governments and other stakeholders to support the
role transformative science brings to people affected by rare
diseases; Alexion’s significantly expanded and diversified pipeline
provides the opportunity to serve more patients than ever before;
and Alexion’s ambition to be a global leader. Forward-looking
statements are subject to factors that may cause Alexion's results
and plans to differ materially from those expected by these forward
looking statements, including for example: Alexion may be unable to
elevate its leadership in rare disease due to, among other reasons,
the continued reliance on complement therapies (Soliris and
Ultomiris) for much of its revenues and the inability to expand its
product pipeline or obtain regulatory approval and commercialize
products currently in the pipeline; Alexion’s plan for enhanced
engagement with governments and other stakeholders to support the
role transformative science brings to people affected by rare
diseases may not be realized as a result of, among other factors,
government policies regarding health care and reimbursement are
shifting; ; the anticipated benefits of our products and product
candidates may not be realized; the possibility that results of
clinical trials are not predictive of safety and efficacy and
potency of our products (or we fail to adequately operate or manage
our clinical trials) which could cause us to discontinue sales of
the product (or halt trials, delay or prevent us from making
regulatory approval filings or result in denial of approval of our
product candidates); unexpected delays in clinical trials;
unexpected concerns regarding products and product candidates that
may arise from additional data or analysis obtained during clinical
trials or obtained once used by patients following product
approval; future product improvements may not be realized due to
expense or feasibility or other factors; inability to timely submit
(or failure to submit) future applications for regulatory approval
for our products and product candidates; inability to timely
initiate (or failure to initiate) and complete future clinical
trials due to safety issues, IRB decisions, CMC-related issues,
expense or unfavorable results from earlier trials (among other
reasons); future competition from biosimilars and novel products;
decisions of regulatory authorities regarding the adequacy of our
research, marketing approval or material limitations on the
marketing of our products; delays or failure of product candidates
to obtain regulatory approval; delays or the inability to launch
product candidates due to regulatory restrictions, anticipated
expense or other matters; interruptions or failures in the
manufacture and supply of our products and our product candidates;
failure to satisfactorily address matters raised by regulatory
agencies regarding products and product candidates; uncertainty of
long-term success in developing, licensing or acquiring other
product candidates or additional indications for existing products;
inability to complete acquisitions or grow the product pipeline
through acquisitions (including due to failure to obtain antitrust
approvals); the possibility that current rates of adoption of our
products are not sustained; the adequacy of our pharmacovigilance
and drug safety reporting processes; failure to protect and enforce
our data, intellectual property and proprietary rights and the
risks and uncertainties relating to intellectual property claims,
lawsuits and challenges against us (including intellectual property
lawsuits relating to ULTOMIRIS brought by third parties and inter
partes review petitions initiated by third parties); the risk that
third party payors (including governmental agencies) will not
reimburse or continue to reimburse for the use of our products at
acceptable rates or at all; failure to realize the benefits and
potential of investments, collaborations, licenses and
acquisitions; the possibility that expected tax benefits will not
be realized; delay of collection or reduction in reimbursement due
to adverse economic conditions or changes in government and private
insurer regulations and approaches to reimbursement; uncertainties
surrounding legal proceedings, company investigations and
government investigations, including investigations of Alexion by
the U.S. Securities and Exchange Commission (SEC) and U.S.
Department of Justice; the risk that estimates regarding the number
of patients with PNH, aHUS, gMG, NMOSD, HPP and LAL-D and other
indications we are pursuing are inaccurate; the risks of changing
foreign exchange rates; risks relating to the potential effects of
the Company's restructuring; risks related to the acquisition of
Syntimmune and other companies and co-development efforts; and a
variety of other risks set forth from time to time in Alexion's
filings with the SEC, including but not limited to the risks
discussed in Alexion's Quarterly Report on Form 10-Q for the
quarter ended June 30, 2019 and in our other filings with the SEC.
Alexion disclaims any obligation to update any of these
forward-looking statements to reflect events or circumstances after
the date hereof, except when a duty arises under law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191010005839/en/
Media Megan Goulart, 857-338-8634 Senior Director,
Corporate Communications
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alexion Pharmaceuticals (NASDAQ:ALXN)
Historical Stock Chart
From Apr 2023 to Apr 2024